Nucleic acid-controlled catalytic rnas for trigger-responsive regulation
US-2024425855-A1 · Dec 26, 2024 · US
US2015017138A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2015017138-A1 |
| Application number | US-201414328900-A |
| Country | US |
| Kind code | A1 |
| Filing date | Jul 11, 2014 |
| Priority date | Jun 15, 2007 |
| Publication date | Jan 15, 2015 |
| Grant date | — |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Methods are described for the delivery of one or more small interfering RNAs (siRNAs) to a eukaryotic cell using a bacterium. Methods are also described for using this bacterium to regulate gene expression in eukaryotic cells using RNA interference, and methods for treating an inflammatory disease or disorder. The bacterium includes one or more siRNAs or one or more DNA molecules encoding one or more siRNAs. Vectors are also described for use with the bacteria of the invention for causing RNA interference in eukaryotic cells.
Opening claim text (preview).
What is claimed is: 1 . A method of delivering one or more siRNAs to mammalian cells, the method comprising introducing to said mammalian cells at least one invasive bacterium containing one or more siRNAs or one or more DNA molecules encoding one or more siRNAs, wherein the expressed siRNAs interfere with the mRNA of TNFα. 2 . An invasive bacterium comprising one or more siRNAs or one or more DNA molecules encoding one or more siRNAs, wherein the expressed siRNAs interfere with the mRNA of TNFα. 3 . A prokaryotic vector comprising at least one DNA molecule encoding one or more siRNAs and at least one RNA-polymerase III compatible promoter or at least one prokaryotic promoter, wherein the expressed siRNAs interfere with the mRNA of TNFα. 4 . The method of claim 1 , wherein said invasive bacterium is a non-pathogenic or non-virulent bacterium. 5 . The method of claim 1 , wherein said invasive bacterium is a therapeutic bacterium. 6 . The method of claim 1 , wherein said mammalian cell is in vivo or in vitro. 7 . The method of claim 1 , wherein said mammalian cell is selected from the group consisting of human, bovine, ovine, porcine, feline, buffalo, canine, goat, equine, donkey, deer, avian, bird, chicken and primate cells. 8 . The method of claim 1 , wherein the mammalian cell is selected from the group consisting of a gastrointestinal epithelial cell and a macrophage. 9 . The method of claim 1 , wherein said one or more DNA molecules encoding said one or more siRNAs are transcribed within the animal cell. 10 . The method of claim 1 , wherein said one or more DNA molecules encoding said one or more siRNAs are transcribed within the bacterium. 11 . The method of claim 1 , wherein said one or more DNA molecules encoding one or more siRNAs comprise a prokaryotic promoter. 12 . The method of claim 11 , wherein said prokaryotic promoter is a T7 promoter. 13 . The method of claim 1 , wherein said animal cells are infected with about 10 3 to 10 11 viable invasive bacteria. 14 . The method of claim 1 , wherein said animal cells are infected at a multiplicity of infection ranging from about 0.1 to 10 6 . 15 . The method of claim 1 , wherein the expressed siRNAs direct the multienzyme complex RNA-induced silencing complex of the cell to interact with the mRNA of TNFα. 16 . The method of claim 1 , wherein expression of TNFα is decreased or inhibited, 17 . The invasive bacterium of claim 2 , wherein said invasive bacterium is a non-pathogenic or non virulent bacterium. 18 . The invasive bacterium of claim 2 , wherein said invasive bacterium is a therapeutic bacterium. 19 . A composition comprising the bacterium of claim 2 and a pharmaceutically acceptable carrier. 20 . A eukaryotic host cell comprising the bacterium of claim 2 , and a pharmaceutically acceptable carrier.
Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression · CPC title
General methods applicable to biologically active non-coding nucleic acids · CPC title
spanning the whole gene, or a large part of it · CPC title
against growth factors, growth regulators, cytokines, lymphokines or hormones · CPC title
against viruses · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.